![8-[4-(4-Fluprophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F3D%2Fthumb-webp%2FFF27863.webp&w=3840&q=75)

8-[4-(4-Fluprophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one
CAS:
Ref. 3D-FF27863
![8-[4-(4-Fluprophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F3D%2Fthumb-webp%2FFF27863.webp&w=3840&q=75)

Product Information
Name:8-[4-(4-Fluprophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one
Synonyms:
- Spiperone4-Phenyl-8-[3-(4-fluorobenzoyl)propyl]-1-oxo-2,4,8-triazaspiro[4,5]decaneSpiropitan
Brand:Biosynth
Description:8-[4-(4-Fluprophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one (8OHPPD) is a prodrug that is hydrolyzed in vivo to 8-[4-(4-fluorophenyl)-4-oxobutyl]-1,3,8-triazaspiro[4.5]decane (8FBP), its active form. This drug has been shown to be an effective treatment for bowel disease and eye disorders. It activates the 5HT2C receptor in the brain and this activation may be responsible for its beneficial effects on bowel disease. 8OHPPD also has shown anticancer activity against breast cancer cells that express high levels of HER2+ receptors. The drug inhibits dopamine release by binding to 5HT2 receptors and it has been shown to inhibit tumor growth in mouse models of breast cancer
Notice:Our products are intended for lab use only. For any other use, please contact us.
Chemical properties
Molecular weight:395.47 g/mol
Formula:C23H26FN3O2
Purity:Min. 95%
Color/Form:Powder